DelveInsight’s “Polycystic Ovarian Syndrome Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Polycystic Ovarian Syndrome, historical and forecasted epidemiology as well as the PCOS market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Polycystic Ovarian Syndrome Market with DelveInsight’s In-Depth Report @ PCOS Treatment Market
Key Takeaways from the Polycystic Ovarian Syndrome Market Report
- In January 2025, Celmatix Therapeutics launched a new endometriosis drug program based on a JNK inhibitor developed in partnership with Baylor College of Medicine. The approach is designed to target pain and inflammation and may also have potential applications in conditions such as PCOS and ovarian aging.
- The Polycystic Ovarian Syndrome market is expected to rise significantly during the forecast period 2024–2034, driven by increasing awareness, improved diagnostic techniques, and lifestyle changes leading to higher rates of obesity — a significant risk factor for PCOS.
- Polycystic Ovarian Syndrome is one of the most common causes of female infertility, affecting 6% to 12% of US women of reproductive age. It is estimated that as many as 75% of individuals with PCOS remain undiagnosed when visiting their doctor, due to variability in patient presentation and lack of provider knowledge.
- The approximate prevalence of PCOS among patients aged 16 to 40 years was 5.2% across all race and ethnicity groups. PCOS is thought to affect about 1 in every 10 women in the UK.
- It is estimated that 40 to 60% of women with PCOS in Western countries and 26% in Japan are overweight or obese, underscoring the strong association between metabolic dysfunction and disease burden.
- In 2023, the United States held a significant share of the overall 7MM PCOS market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of available treatments — a dominance projected to persist throughout the forecast period.
- Currently, the FDA has not approved any drugs specifically for treating Polycystic Ovarian Syndrome, with treatment relying primarily on off-label therapies such as hormonal contraceptives, metformin, and anti-androgen medications to manage symptoms.
- Emerging PCOS therapies including novel drug classes such as selective androgen receptor modulators (SARMs), oral GnRH antagonists, and insulin sensitizers aim to address underlying hormonal imbalances and metabolic dysregulation. Tildacerfont (Spruce Biosciences), a CRF1 receptor antagonist currently in Phase II development, is among the most watched pipeline assets.
- The Polycystic Ovarian Syndrome Companies include Merck, Zenchi Inc., Citruslabs, Ferring Pharmaceuticals, AbbVie, Spruce Biosciences, Biosearch S.A., Novartis Pharmaceuticals, Dexa Medica Group, AstraZeneca, Pfizer, and others.
Stay ahead in the Polycystic Ovarian Syndrome Therapeutics Market with DelveInsight’s Strategic Report @ PCOS Market Outlook
Polycystic Ovarian Syndrome Epidemiology Segmentation in the 7MM
The epidemiology section provides historical, current, and forecasted PCOS prevalence scenarios across the 7MM — covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
- Total Prevalent Cases of Polycystic Ovarian Syndrome
- Diagnosed Prevalent Cases of Polycystic Ovarian Syndrome
- Treatable Cases of Polycystic Ovarian Syndrome
Download the report to understand which factors are driving Polycystic Ovarian Syndrome epidemiology trends @ PCOS Prevalence
Polycystic Ovarian Syndrome Emerging Drugs
Tildacerfont: Spruce Biosciences
Tildacerfont is a CRF1 receptor antagonist designed to potentially offer markedly improved disease control and reduced steroid burden in patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH). It binds to CRF1 receptors on the pituitary gland, inhibiting excessive production of ACTH and ultimately limiting the production of adrenal androgens such as androstenedione, a precursor to testosterone. Tildacerfont is generally well-tolerated in healthy volunteers and in people with rare endocrine conditions, and is currently in Phase II of clinical development administered via the oral route.
GnRH Antagonists (e.g., Elagolix)
GnRH antagonists such as Elagolix block the action of gonadotropin-releasing hormone (GnRH) in the pituitary gland, resulting in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This suppression leads to reduced ovarian androgen production, helping to alleviate symptoms of hyperandrogenism such as hirsutism, acne, and irregular menstrual cycles, representing a promising mechanistic approach within the PCOS treatment pipeline.
Polycystic Ovarian Syndrome Market Outlook
Polycystic Ovarian Syndrome is a prevalent endocrine disorder affecting females, characterized by hormonal imbalances, ovarian dysfunction, irregular menstrual cycles, infertility, excessive hair growth, acne, weight gain, and mood disorders. It commonly arises during adolescence or early adulthood, with genetics, insulin resistance, obesity, and environmental factors contributing to its development. The condition poses significant long-term health risks including diabetes and cardiovascular disease.
The primary treatment goal is to alleviate symptoms and address underlying hormonal imbalances, aiming to restore menstrual regularity, improve fertility, and manage metabolic complications. Current treatments include hormonal contraceptives, insulin-sensitizing agents such as metformin, and anti-androgen medications. In some cases, surgical interventions such as ovarian drilling may be considered to induce ovulation. As no FDA-approved PCOS-specific therapy currently exists, the market is heavily reliant on off-label approaches, creating a significant opportunity for emerging targeted therapies.
DelveInsight predicts substantial transformations in the PCOS market across the 7MM between 2020 and 2034, driven by a robust pipeline of emerging therapies, growing patient advocacy, shifting healthcare policies emphasizing holistic and multidisciplinary management, and increasing integration of digital health and telemedicine platforms to improve patient access to diagnosis, monitoring, and treatment — particularly in remote areas.
“Polycystic Ovarian Syndrome is one of the most common causes of female infertility, affecting 6% to 12% of US women of reproductive age, with up to 75% of patients estimated to remain undiagnosed — representing a significant and largely untapped opportunity for the PCOS therapeutics market through 2034.”
Get In-Depth Knowledge on PCOS Market Trends and Forecasts with DelveInsight @ PCOS Treatment Options
Scope of the Polycystic Ovarian Syndrome Market Report
- Coverage: 7MM
- Study Period: 2020–2034 | Forecast Period: 2024–2034
- PCOS Companies: Merck, Zenchi Inc., Citruslabs, Ferring Pharmaceuticals, AbbVie, Spruce Biosciences, Biosearch S.A., Novartis Pharmaceuticals, Dexa Medica Group, AstraZeneca, Pfizer, and others
- PCOS Therapies: Tildacerfont (Spruce Biosciences), GnRH antagonists (including Elagolix), metformin, hormonal contraceptives, anti-androgen medications, selective androgen receptor modulators (SARMs), insulin sensitizers, and others
- PCOS Therapeutic Assessment: Current off-label marketed therapies and emerging pipeline candidates
- Market Dynamics: Market drivers and barriers, SWOT and conjoint analysis, KOL views, and reimbursement landscape
Unlock Strategic Insights with DelveInsight’s Comprehensive PCOS Market Report @ PCOS Market Drivers and Barriers
Table of Content
- Key Insights
- Report Introduction
- Polycystic Ovarian Syndrome (PCOS) Market Overview at a Glance
- Polycystic Ovarian Syndrome (PCOS) Epidemiology and Market Methodology
- Executive Summary of Polycystic Ovarian Syndrome (PCOS)
- Key Events
- Disease Background and Overview: Polycystic Ovarian Syndrome (PCOS)
- Epidemiology and Patient Population
- Patient Journey
- Emerging Therapies: Key Cross
- Polycystic Ovarian Syndrome (PCOS): Seven Major Market Analysis
- Key Opinion Leaders’ Views
- SWOT Analysis
- Unmet Needs
- Reimbursement and Market Access
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
